Why we will stop making deodorant

For most people, body odour has one solution: deodorant. You buy it; it works or it does not, and if it does not, someone tells you it is your body chemistry. That explanation has been repeated so many times it stopped being questioned. It is also wrong.

Body chemistry is not why deodorant fails people. If your odour comes from a hormonal or metabolic pathway and your deodorant was built for bacteria, it was never going to work. That is a mismatch. The industry never acknowledged it because there was a knowledge gap.

That knowledge gap lets weak claims spread. One of them targets magnesium hydroxide, an ingredient we use. It has been doing the rounds on a deodorant subreddit, and it turned up in a recent comparative ad. The argument runs like this. Your skin is naturally a little acidic.^[1] Magnesium hydroxide is the opposite, alkaline, with a pH that runs even higher than baking soda's. So it must be hard on your skin.

But the argument leaves out one fact. pH tells you how alkaline something is only after it fully dissolves in water, in a beaker. Your skin is not a beaker, and because magnesium hydroxide barely dissolves, only a tiny amount of it ever turns to liquid on your skin.^[2] Only that dissolved amount can act as an alkali, so most of the powder never touches your skin's pH. That is why it cannot reach the harsh alkalinity of a fully soluble base like baking soda. The little that does dissolve does not last, because your skin works to stay acidic and quietly cancels out small amounts of alkali on its own.^[3] And the final say is not ours. Europe's chemical safety regulator does not classify magnesium hydroxide as a skin irritant, and lab tests on human skin models back that up.^[4] An independent safety panel reached the same view, judging it safe in cosmetics when formulated to be non-irritating.^[5] Its high pH was never the problem.

An ingredient means nothing on its own. What matters is how it behaves where it is actually used, on warm, sweat-wetted skin rather than in a beaker. Many harmless ingredients are made to look bad and dangerous through ill-informed marketing narratives. The deodorant category is full of fearmongering and misinformation.

When we launched the classic microsilver paste in 2020, we were fully aware it would only solve the microbial odour pathway and our marketing revolved around it. The paste was built for one pathway. If it did not work for you, your odour was coming from a different one entirely.

Then the emails started. A small number of customers wrote to say the product was not covering them for 24 hours despite using a larger serving size, that there was a lingering smell that was not their usual body odour, or that things were noticeably worse after using it. Our advisors said the numbers were too small to worry about. We kept thinking about the one percent.

We knew exactly what was happening. Some of these customers were dealing with something else entirely. A volatile fatty acid pathway producing a cheesy or fermented smell that persisted no matter how clean they were. A biofilm slowly degrading performance at the follicular level, making the paste less effective with each passing week. An amine or ammonia pathway that the paste was not only failing to address but actively aggravating. Each of these required a different answer, and in some cases we gave them one. We did not have a product to solve their problem. Nobody did. So that became the only thing worth building.

Around 2021, while this new direction was taking shape, our team started working on a stick. Customers were asking for it and it made commercial sense. But it would solve nothing new. Anyone the paste could not help, the stick could not help either. We called our brand Super Deodorant because super means what it says. A product that knowingly fails a percentage of people is not super anything.

We mapped the odour landscape and identified eleven pathways worth addressing topically, spanning bacterial, hormonal, metabolic, oxidative, and structural origins. Mapping them was the easy part. Finding a proper solution for each one proved far more challenging and took years. We went deep into enzyme chemistry, lipid oxidation, biofilm architecture, hormonal shifts, and metabolic excretion. We built something with phases that work in sequence, each one preparing the conditions for the next.

We accepted early on that what we were building could no longer be called a deodorant because it was not one. We targeted late 2025 for launch. Then early 2026. Ingredients did not arrive when they were supposed to, timelines were broken, and supply chain disruptions did the rest. We are now aiming for June 2026.

Many of you have said that we no longer sound like ourselves. That the language is more complex now. You are not wrong. Terms like Bio-Volatile Inhibitor Concentrate feel pretentious to people who just want a deodorant that works. We understand that. But we are not building for acceptance and we are prepared to be misunderstood. We know something that most people do not, and we are creating something that you will fully understand when your body gives you reason to need it.

We built the Volatile Control System for the one percent. The people who did everything right and still smelled. But we also built it for everyone else, because bodies are not static. Hormones change. Skin changes. What works at thirty does not always work at forty-five. Most people have no reason to think about any of this today. Some will, eventually. We want the answer to exist before they need it.

If the Volatile Control System cannot stop a smell, no other topical product will. That is the ceiling. Everything beyond it belongs to medicine.